GlaxoSmithKline and Galapagos created a worldwide, multi-year, multi-program drug discovery and development alliance in the field of osteoarthritis. GSK, through its Center of Excellence for External Drug Discovery (CEEDD), will collaborate with Galapagos to deliver disease-modifying drugs with clinical Proof of Concept to GSK’s global R&D organization. This alliance builds upon Galapagos’ internal target and drug discovery program in osteoarthritis. Galapagos will conduct c...